Renibus Therapeutics raised $110.89 million to develop therapies for kidney, cardiac, and metabolic diseases, including veverimer for ultra-rare anti-glomerular basement membrane (anti-GBM) disease and RBT-1 to reduce post-operative complications in cardiac surgery patients.
